Shares of Bristol Myers Squibb Co. slid 3.42% to $46.86 Friday, on what proved to be an all-around dismal trading session for ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

This was the stock's third consecutive day of gains.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

This Big Pharma company is positioned for a rebound while continuing to pay investors a sizable dividend yield.

Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-risk sexual ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb’s Fundamentals Over Recent Years. Bristol Myers Squibb’s revenue increased from $26 billion in 2019 to $46 billion in 2022, partly aided by its Celgene CELG acquisition in ...